Medicinal Chemistry

Primary screening studies initially generate a list of compounds with the required biological activities (‘Hits’). These Hits rarely fulfil all the criteria for a quality “tool” compound as they typically show only a moderate affinity for the target and restricted selectivity.

To become a useful tool compound, the chemical properties of the initial Hits must therefore be iteratively improved by suitable structural modification. The post-screening Hit-to-tool optimisation process is carried out by accredited chemistry partner sites in EU-OPENSCREEN ERIC Member countries and is organised as a research collaboration between the assay provider and the respective chemistry site.

Apply for funding

Currently, the European Commission offers project funding for medicinal chemistry support in our EU-OPENSCREEN ERIC partner sites through the ISIDORe project. Read more here.



Medicinal chemistry partner sites


Masaryk University (MU) – Laboratory of Organic Synthesis and Medicinal Chemistry

Dr. Kamil Paruch

Information PDF


Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) – Medicinal Chemistry

Dr. Marc Nazaré

Information PDF​​​​​​​


Technical University of Denmark (DTU) – Chemistry

Prof. Mads H. Clausen

Information PDF


Center for Biological Research Margarita Salas (CSIC)

Prof. Dr. Ana Martínez

Information PDF


Latvian Institute of Organic Synthesis (LIOS)

Dr. Osvalds Pugovičs

Information PDF​​​​​​​


Institute of Biochemistry and Biophysics (IBB PAS)

Prof. Dr. Piotr Zielenkiewicz

Information PDF